ArticleScientific reports2026
ALKBH1 gene polymorphisms confer hepatoblastoma susceptibility in Chinese children.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Hepatoblastoma is the most common malignant liver tumor of embryonic origin in children; however, its underlying etiology remains unclear. N1-methyladenosine (m1A) modification is widely found in various human tissues and has been demonstrated to regulate tumorigenesis, but no studies have explored the role of ALKBH1 in the development of hepatoblastoma. We genotyped three ALKBH1 gene polymorphisms (rs1048147 C > A, rs6494 T > A, and rs176942 A > G) via the TaqMan method for 313 patients with hepatoblastoma and 1446 healthy subjects, after which the odds ratios (ORs), 95% confidence intervals (CIs), and P values for each polymorphism were calculated. We found that all the three polymorphisms were significantly associated with hepatoblastoma susceptibility. The rs1048147 C > A was shown to reduce hepatoblastoma risk (adjusted OR = 0.72, 95% CI = 0.56–0.92, P = 0.009) under dominant model, whereas rs6494 T > A (adjusted OR = 6.17, 95% CI = 1.37–27.37, P = 0.018) and rs176942 A > G (adjusted OR = 2.12, 95% CI = 1.22–3.69, P = 0.008) significantly increased hepatoblastoma risk under recessive model. Stratified analysis indicated that the rs1048147 CA/AA genotype decreased hepatoblastoma risk in children aged ≥ 17 months, females, and those with clinical stages I + II, whereas the rs176942 GG genotype increased the risk of hepatoblastoma in females. In addition, carriers of 2–3 risk genotypes had higher risk of tumor development, specifically among children aged ≥ 17 months, males, and those diagnosed with clinical stages I–II disease. Finally, eQTL analysis revealed that the three polymorphisms were associated with the expression levels of ADCK1, SNW1, and SLIRP. Overall, our findings revealed a significant association between ALKBH1 gene polymorphisms and hepatoblastoma susceptibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.